IL17A and osteoporosis: The authors speculated that neutralization of IL-17A might represent a novel therapeutic strategy for PHPT-related osteoporosis; this perspective is fascinating as an IL-17A inhibitor, secukinumab, has been developed for the treatment of ankylosing spondylitis [7].